HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)

HC Wainwright reissued their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research report released on Friday,Benzinga reports. The firm currently has a $20.00 price objective on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also weighed in on KALV. Bank of America began coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price objective on the stock. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday. Finally, Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, KalVista Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $23.80.

KalVista Pharmaceuticals Stock Performance

KALV opened at $12.60 on Friday. The firm’s fifty day moving average is $9.75 and its two-hundred day moving average is $10.26. The firm has a market cap of $622.67 million, a PE ratio of -3.46 and a beta of 0.76. KalVista Pharmaceuticals has a twelve month low of $7.30 and a twelve month high of $15.50.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par acquired 43,707 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was acquired at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the purchase, the insider now directly owns 4,986,480 shares of the company’s stock, valued at $43,681,564.80. This trade represents a 0.88 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Paul K. Audhya sold 3,125 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the sale, the insider now owns 100,334 shares of the company’s stock, valued at $985,279.88. This trade represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 236,055 shares of company stock valued at $2,162,146 and sold 17,292 shares valued at $184,625. 10.50% of the stock is currently owned by insiders.

Institutional Trading of KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC raised its stake in KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,319 shares in the last quarter. HighVista Strategies LLC raised its position in shares of KalVista Pharmaceuticals by 4.5% in the 3rd quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock valued at $386,000 after buying an additional 1,432 shares in the last quarter. Legal & General Group Plc raised its position in shares of KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 1,494 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after buying an additional 1,670 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after buying an additional 2,043 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).